Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

FDX104 (4% Doxycycline) - Phase 2 | VYNE Pipeline | CatalystAlert

FDX104 (4% Doxycycline)

Phase 2

VYNE Therapeutics Inc. (VYNE)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Rash Due to Epidermal Growth Factor Receptor Inhibitors

Clinical Trial

Last updated: 12/4/2025

Developer

VYNE

VYNE Therapeutics Inc.

Biotechnology•North America•NASDAQ